HPV Information Center Archive
Investigators examined parental hesitancy when discussing human papillomavirus vaccination with providers.
High-certainty evidence for protection in adolescent girls and young women aged 15 to 26 years
Clinicians using communication training and fact sheets to inform adolescents about HPV, significantly increased vaccination initiation and completion rates among their patients.
The importance of male vaccination cannot be overemphasized, because the risk of male-to-female HPV transmission is significant.
The researchers found that 2 doses of the HPV vaccine were just as protective as 3 doses.
Nitrate inhalants (poppers) associated with increased virus-associated cancer risk in HIV-uninfected MSM
Among HIV-uninfected men aged 50 to 70, heavy popper use was associated with an increased risk of virus-associated cancer with causes linked to HPV, HHV-8, and Epstein-Barr virus.
The data suggest that the vaccine may be reducing the prevalence of those infections by as high as 100%.
However, the HPV vaccine has the potential to reverse the epidemic and prevent thousands of cancers in the United States each year.
The students improved their basic knowledge of HPV and understood the benefits of the HPV vaccine.
Children younger than 15 may be given 2 HPV vaccine doses instead of 3, and the shots should be spaced at least 6 months apart.
A new HPV screening test that uses cervical cells collected for a Pap test has been approved by the FDA.
A greater understanding of the healthcare issues specific to the lesbian, gay, bisexual, and transgender community may improve the quality of care.
College-aged students may benefit from continued education regarding the spread of HPV, especially oral transmission
The new vaccine protects against 9 types of HPV and 5 cancer-causing strains.
The American Society of Clinical Oncology has released its recommendations to help improve rates of HPV vaccination worldwide.
Data collected between 2009 and 2012 show a significant decline in cases of HPV in females aged 14-19 and 20-24.
Confusion surrounds the current screening recommendations and guidelines.
A variety of factors have led to low rates of teenage boys being vaccinated for the human papillomavirus (HPV), said a report published in Pediatrics.
Human papillomavirus vaccination not linked to increase in sexually transmitted infections in adolescent females
The HPV vaccination is not associated with an increase in sexually transmitted infections in adolescent females, study results suggest. The vaccine is recommended for all children 11 to 12 years old.
The Cervarix vaccine may be as effective in one or two doses as it is with three.
In survey, more than half didn't get vaccinated; many were unaware of risk
While not statistically significant, participants who noted they had received the HPV vaccine also reported that they used condoms without fail at every sexual encounter.
The potential costs and effectiveness of HPV4 vaccination versus no vaccination were compared in a theoretical cohort based on a cohort of 192,940 boys aged 12 years.
The CDC's Advisory Committee on Immunization Practices met to vote on updates to several vaccine recommendations, including for HPV.
Almost half of American girls receive the HPV vaccine after the recommended age.
In a survey conducted by the Advisory Committee on Immunization Practices (ACIP), 33% of clinicians routinely recommend the HPV4 vaccine to 11- and 12-year-old males.
The cobas HPV test detects DNA from 14 types of HPV and included types 16 and 18, which cause 70% of cervical cancers.
In primary and secondary analyses, vaccination was not associated with an increased risk of multiple sclerosis or other demyelinating diseases.
Having female sex partner with HPV puts men at greater risk for contracting HPV type responsible for throat cancers.
One third of women aged 15 to 26 years with precancerous cervical lesions were infected with more than one type of HPV.
After surveying low-income communities, researchers found that human papillomavirus knowledge did not sway vaccination compliance.
Vaccination-induced anti-HPV response persists through 96 months for all HPV vaccine types.
1/3 of parents of girls reported that their child's clinician had failed to recommended the HPV vaccination during office visits.
As human papilloma virus-associated oropharyngeal cancers become more prevalent, clinicians should discuss risks with patients.
Test specifically identifies HPV types 16 and 18, as well as detecting 12 other types of high-risk HPVs.
New HPV test could be used before or instead of Pap test for cervical cancer screening.
Make sure parents understand utility of the HPV vaccine for preventing cancer, not just sexually transmitted diseases.
Efforts to improve HPV vaccine uptake in boys should focus on parent education, link between virus and cancer.
Cancers of the base of the tongue, the tonsils, the soft palate and the pharynx have increased 60% in those younger than age 45 years since the 1970s.
Two doses of quadrivalent HPV vaccine, rather than the recommended three, still protective.
Strategies to improve HPV vaccine uptake and completion should consider parental attitudes and concerns.
Female clinicians twice as likely to order HPV testing for any cytology results in low-risk women.
One dose of HPV vaccine induces long-term antibodies.
Black women are more likely to have high-risk HPV genotypes that are not included in available vaccines.
What is the likelihood of HPV-caused cervical cancer recurrence after loop electrosurgical excision procedure?
Despite decreases in Pap testing, rates remain high, and HPV testing practices have not changed since the ACOG recommend against the practice.
Rates for Tdap and meningococcal vaccines have increased, but the number of girls receiving the complete HPV vaccine series has stalled.
Promoting oral health and hygiene important in public health interventions to prevent HPV-related oral cancers.
HPV vaccination is widely offered but underused, and many continue annual Paps.
Prevalence of vaccine-type HPV decreased 56 percent in females aged 14-19 from 2003-2006 to 2007-2010.
Simple vinegar-based visual inspection screenings by primary paramedical health workers reduced cervical cancer mortality by 31% over 15 years.
More efforts focused on educating impoverished populations about HPV are needed.
Improving parents' general knowledge of the human papillomavirus and vaccine benefits can help improve uptake.
Genital wart prevalence declined more than 90% among adolescent and teen girls in the four to five years after the HPV vaccine became available in Australia.
More than 40% of parents surveyed in 2010 reported they did not intend to vaccinate their adolescent female children with the HPV vaccine.
Despite reductions in overall cancer mortality, the burden of some HPV-associated cancers continues to rise.
Pregnancy rates, testing for or diagnosis of sexually transmitted infections, or receipt of contraceptive counseling did not differ among adolescent girls who received HPV vaccine at age 11 to 12 and those who did not.
Dizziness, photophobia, nausea and an unsteady gait develop following a routine annual check up.
HPV DNA testing at baseline predicted progression to cervical intraepithelial neoplasia grade 3 at 18-year follow-up more accurately than Pap smear.
Additional surveillance and methodology are needed to assess the impact of HPV vaccines on disease incidence going forward.
Encouraging patients of both sexes to receive the HPV vaccine will help achieve higher herd immunity rates and offer greater protection.
Three childhood vaccine schedules and accompanying footnotes offer new clarifications and guidance.
Higher prevalence of oral HPV in men than women, and peaks at ages 30 to 34 years and 60 to 64 years correlate with trends in oropharyngeal squamous-cell carcinoma incidence.
The CDC's Advisory Committee on Immunization Practices issued HPV and hepatitis B vaccine recommendations based on efficacy and safety data in specific patient populations.
Increasing HPV vaccine uptake among preadolescent girls is more effective in reducing HPV infection than including boys in existing vaccination programs would be, researchers from the Netherlands say.
DNA testing for human papillomavirus (HPV) picks up precancerous lesions earlier and prevents more cervical cancer than standard cytology screening alone.
The U.S. Preventive Services Task Force says screening too frequently for cervical cancer may cause unnecessary anxiety, increases in invasive diagnostic procedures and over treatment with procedures that pose potentially more harm than benefit.
Common reasons that parents give when declining human papillomavirus vaccine for their children are, "My teen is not sexually active," or "Maybe we'll wait until he/she is a bit older." This thinking negates the vaccine's preventive purpose.
DNA-based testing for HPV-16 and HPV-18 detects cervical cancer better than liquid-based cytology, data from the ATHENA trial indicate.
Which type of human papillomavirus (HPV) is associated with nonmucosal, condyloma acuminatum-appearing warts found under the pannus in intertriginous areas?
Clinician-patient education programs can help dispel human papillomavirus vaccine misconceptions and improve uptake rates, according to a researcher at the American Academy of Nurse Practitioners 26th Annual NP meeting.